![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/30/2890550/0/en/Anocca-AB-and-Shinobi-Therapeutics-Announce-Strategic-Partnership-to-Develop-Allogeneic-TCR-T-Cell-Therapies-in-Oncology.html
https://www.globenewswire.com//news-release/2024/03/14/2845972/0/en/Anocca-AB-Licenses-Gene-Editing-Technology-from-EmendoBio-Inc.html
https://www.globenewswire.com//news-release/2024/02/13/2827973/0/en/Anocca-Appoints-Martin-Welschof-to-Board-of-Directors.html
https://www.globenewswire.com//news-release/2024/01/04/2803730/0/en/Anocca-Secures-GMP-Manufacturing-License-To-Push-Novel-KRAS-TCR-T-Cell-Therapies-Into-Clinical-Development.html
https://www.globenewswire.com/news-release/2023/05/31/2679011/0/en/Anocca-raises-SEK-400-million-for-large-scale-development-of-cancer-cell-therapies.html